Psycho-oncological aspects of malignant melanoma : AA systematic review from 1990-2008;Psychoonkologische Aspekte des malignen Melanoms : Ergebnisse eines systematischen Reviews von 1990-2008

Hautarzt

Volumn 60, Issue 9, 2009, Pages 727-734

  Beutel, M E ^a   Blettner, M ^a   Fischbeck, S ^a   Loquay, C ^a   Werner, A ^b   Marian, H ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b Koordinationsstelle Psychosoziale Versorgung Tumorzentrum Rheinland Pfalz EV   (Germany)

Author keywords

Coping; Malignant melanoma; Psychosocial; Quality of life; Survivorship

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; DACARBAZINE; FOTEMUSTINE; HISTAMINE; INTERFERON; INTERLEUKIN 2; PAROXETINE;

AUSTRALIA; AVOIDANCE BEHAVIOR; CANCER CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; COGNITIVE THERAPY; COPING BEHAVIOR; CROSS-SECTIONAL STUDY; DEPRESSION; DRUG MEGADOSE; FATIGUE; FEAR; GERMANY; HEALTH BEHAVIOR; HUMAN; MELANOMA; OVERALL SURVIVAL; PAIN; PSYCHOLOGICAL ASPECT; PSYCHOSOCIAL CARE; PSYCHOTHERAPY; QUALITY OF LIFE; REVIEW; SELF EXAMINATION; SKIN EXAMINATION; SOCIAL PSYCHOLOGY; SOCIAL SUPPORT; SUN EXPOSURE; SURVIVAL RATE; SYSTEMATIC REVIEW; UNITED KINGDOM; UNITED STATES;

COMORBIDITY; HUMANS; INTERNATIONALITY; MELANOMA; MENTAL DISORDERS; PREVALENCE; QUALITY OF LIFE; SKIN NEOPLASMS;

EID: 70149090815     PISSN: 00178470     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00105-009-1814-1     Document Type: Review

References (38)

1. Avril MF, Aandal S, Grob A et el (2004) Fotemustine compared with dacarbezine in patients with disse-minated malignant Melanoma: A Phase III Study. J Clin Oncol 6(22):1118-1125
2. Baider L, Russak SM, Perry S et al (1999) The role of religious and spiritual beliefs in coping with ma-lignant melanoma: an israeli sample. Psychoonco-logy 8:27-35 (Pubitemid 29116263)
3. Beusterien KM, Ackerman SJ, Plante K et al (2003) The health-related quality-of-life impact of hista-mine dihydrochloride plus interleukin-2 compared with interleukin-2 alone in patients with metasta-tic melanoma. Support Care Cancer 11:304-312
4. Blum A, Blum D, Strobel W et al (2003) Psychosoziale Belastung und subjektives Erleben von Melanompatienten in der ambulanten Nachsorge. Psychother Psych Med 53:258-266
5. Boesen EH, Boesen SH, Frederiksen K et al (2007) Survival after a psychoeducational intervention for patients with cutaneous malignant melanoma: a replication study. J Clin Oncol 25:5698-5703
6. Brown JE, Butow PN, Culjak G et al (2000) Psychosocial predictors of outcome: time to relapse and survival in patients with early stage melanoma. Br J Cancer 83(11):1448-1453
7. Butow PN, Coates AS, Dunn SM (1999) Psychosocial predictors of survival in metastatic melanoma. J Clin Oncol 17:2256-2263
8. Canada AL, Fawzy NW, Fawzy IF (2005) Personality and disease outcome in malignant melanoma. J Psychosom Res 58:19-27
9. Cohen L, Parker PA, Sterner J et al (2002) Quality of life in patients with malignant melanoma participating in a phase I trial of an autologous tumorderived vaccine. Melanoma Res 12:505-511 (Pubitemid 35264728)
10. Dixon S, Walters SJ, Turner L et al (2006) Quality of life and cost-effectiveness of interferonalpha in malignant melanoma: results from randomnised trial. Br J Cancer 94:492-498
11. Eakin EG, Youlden DR, Baade PD et al (2006) Health status of long-term cancer survivors: results from an Australian Population-Based Sample. Cancer Epidemiol Biomarkers Prev 15(10):1969-1976
12. Ernst J, Peuker M, Schwarz R † et al (in press) Langzeitüberleben von Erwachsenen nach Krebs aus psychosomatischer Sicht - Literaturübersicht und Forschungsdesiderate. Z Psychosom Med Psychother
13. Fawzy FI, Canada AL, Fawzy NW (2003) Malignant melanoma: effects of a brief, structured psychiatric intervention on survival and recurrence at 10-year follow-up. Arch Gen Psychiatry 60:100-103
14. Francken AB, Bastiaannet E, Hoekstra HJ (2005) Follow-up in patients with localised primary cutaneous melanoma. Lancet Oncol 6:608-621
15. Freiman A, Yu J, Loutfi A et al (2004) Impact on me-lanoma diagnosis on sun-awareness and protec-tion: efficacy of education campaigns in a high-risk population. J Cutan Med Surg 303-309
16. Hamama-Raz Y, Solomon Z, Schachter J et al (2007) Objective and subjective stressors and the psychological adjustment of melanoma survivors. Psychooncology 16:287-294
17. Hauschild A, Rass K, Tilgen W (2008) Systemische Therapie des Melanoms. Hautarzt 59:484-492
18. Holland JC, Passik S, Kash KM et al (1999) The role of religious and spiritual beliefs in coping with malignant melanoma. Psychooncology 8:14-26
19. Kurzleitlinie der Deutschen Dermatologischen Ge-sellschaft (DDG) und der Deutschen Krebsgesell-schaft (2007) Malignes Melanom der Haut (http:// www.uni-duesseldorf.de/AWMF/)
20. Lehto U-S, Ojajen M, Dyba T (2007) Baseline psychosocial predictors of survival in localized melanoma. J Psychosom Res 63:9-15
21. Lehto U-S, Ojanen M, Kellokumpu-Lehtinen P (2005) Predictors of quality of life in newly diagno-sed melanoma and breast cancer patients. Ann Oncol 16:805-816
22. Manne S, Lessin S (2006) Prevalence and correlates of sun protection and skin self-examination practices among cutaneous malignant melanoma survi-vors. J Behav Med 29(5):419-434
23. Mohr P (2008) Supportive Therapie des Melanoms. Hautarzt 59:493-498
24. Musselman DL, Lawson DH, Gumnick JF et al (2001) Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med 344(13):961-966
25. Nashan D, Kirschner F, Strittmatter G et al (2004) Die Wertigkeit der Melanomnachsorge aus der Pa-tientenperspektive. view of melanoma follow-up. J Dtsch Dermatol Ges 2:105-110
26. Newton-Bishop JA, Nolan C, Turner F et al (2004) A quality-of-life study in high-risk (thickness =2 mm) cutaneous melanoma patients in a randomnized trial of 1-cm versus 3-cm surgical excision margins. J Investig Dermatol Symp Proc 9:152-159
27. Noorda EM, van Kreij RHJ, Vrouenraets BC et al (2007) The heath-related quality of life of long-term survivors of melanoma treated with isolated limb perfusion. EJSO 33:776-782
28. Oliveria SA, Hay JL, Geller AC et al (2007) Melanoma survivorship: research opportunities. J Cancer Surviv 1:87-97
29. Orringer JS, Fendrick M, Trask PC et al (2005) The effects of a professionally produced videotape on education and anxiety/distress levels for patients with newly diagnosed melanoma: a randomnized, prospective clinical trial. J Am Acad Dermatol 53:224-229
30. Richard MA, Grob JJ, Avril MF et al (2000) Delays in diagnosis and melanoma prognosis (I): the role of patients. Int J Cancer 89:271-279
31. Bolund C, Brandberg Y et al (1993) The impact of generalized malignant melanoma on quality of life evaluated by the EORTC questionnaire technique. Qual Life Res 2:193-203
32. Söllner W, Zschocke I, Zing-Schir M et al (1999) Interactive patterns of social support and individual coping strategies in melanoma patients and their correlations with adjustment to illness. Psychosomatics 40:239-250
33. Stava C, Beck M, Weiss LT et al (2006) Health pro-files of 996 melanoma survivors: the M.D. Anderson experience. BMC Cancer 6:95
34. Strittmatter G (2004) Psychosoziale Betreuung von Patienten mit Hauttumoren in Zeiten der Diagno-sis Related Groups. Hautarzt 55:735-745
35. Trask PC, Paterson AG, Esper P et al (2004) Longitudinal course of depression, fatigue, and quality of life in patients with high risk melanoma receiving adjuvant interferon. Psychooncology 13:526-536
36. Trask PC, Paterson AG, Griffith KA et al (2003) Cognitivebehavioral intervention for distress in pati-ents with melanoma. Cancer 98:854-864
37. Trask PC, Paterson AG, Hayasaka S et al (2001) Psychosocial characteristics of individuals with non-stage IV melanoma. J Clin Oncol 19:2844-2850
38. White VM, English DR, Coates H et al (2007) Is cancer risk associated with anger control and negative affect? Findings from a prospective cohort study. Psychosom Med 69:667-674